Stent manufacturers want the government to apply differential pricing for drug-eluting stents by classifying them on the basis of technology used.
Such a move will reward quality and innovation to keep the segment viable while also giving physicians broader treatment options, according to two industry bodies — AdvaMed and MTaI. Drug-eluting stents (DES) have a polymer coating over mesh that emits a drug over time that prevent blockage of arteries from recurring. These are considered superior over bare metal stents, which are a mesh-like tube of thin wires. In February this year, the NPPA had brought stents under price control and capped their price at ?7,260 for bare metal variety and ?29,600 for DES.